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1. Introduction 
Type 1 diabetes (T1D) is a chronic autoimmune disease representing a major health care 
problem worldwide (Tierney et al., 2002). T1D is caused by islet-reactive immune T cells that 
destroy insulin-producing pancreatic ǃ-cells. Transplantation of insulin-producing 
pancreatic islets by their injection in vascularized organs has been recently recognized as a 
promising path to curing diabetes (Meloche, 2007; Robertson, 2000). However, despite the 
significant promise, the clinical application of the procedure remains limited due to (a) 
limited supply of islets suitable for transplantation, (b) a hypoxia because of a low tension of 
oxygen at the implantation sites and (c) an acute rejection during transplantation. One of the 
challenges is associated with isolation and culturing islets in vitro before injection. In the 
pancreas, endocrine cells of the islet clusters are separated from exocrine cells by a 
discontinuous mantle of collagen fibers defining their respective basement membrane. 
During collagenase isolation of islets from the pancreas, further disruption of the islet 
mantle results in preparations exhibiting various morphological changes (islet 
fragmentation, fusion) under routine tissue culture conditions, particularly in human islets 
(Lacy & Kostianovsky, 1967). Attenuation of islet viability and functionality accompanies 
these morphological changes. The second issue is associated with islet transplantation which 
requires immunosuppression to protect the donor islets from the host immune response and 
prevent implant rejection and post-surgery inflammations (Ricordi & Strom, 2004). Despite 
the fact that a range of immunosuppressive drugs have demonstrated pharmacologically 
inhibitory effects on pro-inflammatory cytokines (Riachy et al., 2002; Contreras et al., 2002; 
Lv et al., 2008; Stosic-Grujicic et al., 2001), the use of immunosuppressive molecules is very 
specific since they can induce non-specific suppression of the immune system resulting in 
serious side effects and increased risk of infection which can work against the benefits of a 
transplant (Narang & Mahato, 2006). These issues have inspired the development of a 
number of strategies to prevent immunogenic reactions and stabilize islet morphology and 
functionality, both in vitro and following transplantation in vivo (Chandy et al., 1999; 
Abalovich et al., 2001). Two major approaches have been introduced to prevent 
immunogenic reactions on the islet surfaces: macro and microencapsulation of the islet cells 
and islet cell surface modification (Fig. 1) (De Vos et al., 2003; Panza et al., 2000; Scott & 
Murad, 1998; Opara et al., 2010).  
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Islet macro/microencapsulation strategy is based on embedding islets in solid matrices, 
allowing for the creation of a semi-permeable environment around islets capable of 
immune-protection and for mass and oxygen transfer (Beck et al., 2007; Weber et al., 2007). 
For that, the isolated islets are usually entrapped individually or as islet clusters in thick 
gels, for example, high-viscous alginate droplets stabilized with divalent ions of barium or 
calcium (Zimmermann et al., 2001). Islet surface modification strategy involves covalent 
conjugation of molecules to islet cell surfaces. However, this technology is limited to the 
introduction of specified functional small molecules to cells and might interfere with cell 
physiology (Rabuka et al., 2008; Paulick et al., 2007). Layer-by-layer (LbL) technique has 
been recently applied as a new approach to modify islet surfaces (Krol et al., 2006; Wilson et 
al., 2008). The technique is based on alternating LbL deposition of water soluble polymers 
on surfaces from aqueous solutions which results in nano-thin coatings of controllable 
thickness and composition (Decher & Schlenoff, 2002; Kharlampieva & Sukhishvili, 2006; 
Tang et al., 2006).  
Unlike bulk encapsulating materials, the ultrathin conformal coating affords a faster 
response to stimulation and the possibility to bind factors or protective molecules to the 
protective ultrathin shell with the later slow triggered release of these molecules (Chluba et 
al., 2001). By selecting specific pairs of polyelectrolytes, a defined cutoff of the coating 
(Kozlovskaya & Sukhishvili, 2006) is possible, as is inhibitor binding to prevent graft 
rejection, microphage attacks, or antibody recognition (Kim & Park, 2006). Here, we review 
methods and devices designed for protecting isolated islets from host immune responses 
while allowing transport of essential nutrients. We also discuss challenges of various 
approaches developed for encapsulation of individual islets in thin coatings that conform to 
the islet surfaces, fabricated using a number of physical and chemical processes.  
 
Fig. 1. Strategies for encapsulation and surface engineering of pancreatic islets. 
2. Preservation of islets in vitro 
Recently, the advantages of cultured islets before transplantation have been demonstrated 
over freshly isolated islets (Herring et al., 2004; Ichii et al., 2007). It is known that cellular 
stress due to pancreas preservation and islet isolation process leads to a loss of islets during 
the first 24 h after isolation. Islet culture after isolation can prevent islet cells from toxic 
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factors generated by cells damaged during these processes, providing sufficient oxygen and 
nutrients to allow islet cells to recover. After isolation of islets from donors, it is crucial to 
maintain islet viability and functionality until transplantation to give sufficient time to 
perform microbiological tests as well as donor matching and recipient pre-conditioning.  
Modifying the islet preparations for reducing immunogenicity by altering temperature (Kim 
et al., 2005; Stein et al., 1994), or media composition is one of the advantages for islet pre-
culture (Ricordi et al., 1987; Murdoch et al., 2004). For example, supplementation of culture 
media with lactogen hormones has been shown to minimize ǃ-cell loss during pre-
transplant culture leading to a higher ǃ-cell survival rather than proliferation (Yamamoto et 
al., 2010; Nielsen, 1982). When islets were cultured in media supplied with recombinant 
human prolactin (rhPRL) for 48 h, production of interferon-gamma (IFN-Ǆ), tissue necrosis 
factor-alpha (TNF-ǂ), interleukins cytokines, IL-6, IL-8 and microphage inflammatory 
protein-1-ǃ was comparable with the control group of islets with no increase in pro-
inflammatory mediators in the presence of rhPRL suggesting no elevated immunogenicity. 
Furthermore, the PRL treatment of islet preparations resulted in decreased apoptosis in ǃ-
cell subsets, suggesting ǃ-cell specific anti-apoptotic effects of rhPRL (Yamamoto et al., 
2010). Another possible issue with the pre-cultured islets is the possibility of islet fusion 
during incubation, which may lead to hypoxia and starving of the cells. Those result in 
central necrosis of fused islet aggregates causing a significant loss of islet potency and 
viability (Ichii et al., 2007).  
Apoptosis of human islets after isolation from supporting extracellular matrix is a very 
common cell pathway in vitro. During the first steps towards apoptosis integrin 
expression is diminished and, consequently, phenotype characteristics are lost and islets 
stop secreting insulin (Ris et al., 2002). Exploring the parameters important for preventing 
pre-apoptotic events should help in preserving islet viability and function for long 
periods of time. The effects of two types of collagen, type I and type IV, and fibronectin, 
proteins that are generally present in the cell-supporting matrix have been explored 
(Daoud et al., 2010). Islets have a tendency to spread and form a monolayer on surfaces in 
vitro. The islet monolayer can still be viable without preserving the phenotype 
characteristics, however, the normal insulin secretion of islets will be lost. Daoud et al. 
showed that integrity and insulin production of islets can be preserved by presence of 
fibronectin in the medium (Daoud et al., 2010). Both types of collagen increased the 
viability of islets from 24 to 48 hours in vitro. Several studies revealed an increasing 
survival of islets in vitro when embedded in a solid matrix. Culture in collagen I gels 
obtained from rat tail and fibrin gels have shown promising for prolonging islet survival 
(Wang & Rosenberg, 1999; Beattie et al., 2002).  
3. Approaches to prevent immunogenic reactions on the islet surfaces 
The immune reactions against encapsulated islets can be divided into non-specific immune 
activation initiated by surgery; a host response against the encapsulating materials and 
implanted islets provokes the immune response by releasing the bioactive molecules. 
The instant blood-mediated inflammatory reaction (IBMIR) is an inflammatory reaction that 
occurs when isolated islets come in contact with human blood. This process is responsible 
for islets destruction together with overall failing of transplantation. One of the major 
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triggers for the IBMIR reaction is a secretion of tissue factors by islets surfaces. Disruption of 
host tissue by surgery leads to release of bioactive molecules such as fibrinogen, histamine 
and fibronectin. Release of serum components and presence of extracellular matrix and cell 
debris attract tissue macrophages to the surgery site to clean up and start the process of 
wound healing. The immune cells have the ability to produce various small bioactive 
compounds such as interleukins, tissue necrosis factors (TNF) and histamine. There are 
several extravascular approaches to prevent IBMIR reaction against pancreatic islets (Nafea 
et al., 2011).  
3.1 Macro and microencapsulation 
‘Macroencapsulation’ can be defined as encapsulation of large numbers of islets together in 
one device. The shape of the devices can be a hollow fiber, planar membranes or 
macrocapsules. Macroencapsulation provides immune-isolation of islets within semi-
permeable membranes. The major advantage of macrocapsules is the possibility to easily 
retrieve the islets from an implantation site in case of surgery complications. Capsules 
reduce the risk of the IBMIR reaction from occuring, therefore, allowing the use of not only 
allogenic but also xenogenic materials and avoiding the use of immunosuppressive 
medications. However, macroencapsulation has not found a broad use in islet encapsulation 
and transplantation due to a large volume of protective devices. Relatively large sizes will 
cause limited oxygen and nutrition access and, as a result, cell necrosis (De Vos et al., 1999). 
Such macrocapsules do not allow for tuning the molecular weight cutoff (or semi-permeable 
properties) to prevent recognition by antibodies, and cytokines cannot be sufficiently 
excluded either (Cui et al., 2004). Similarly, recently developed poly(ethylene glycol) (PEG) 
hydrogels although demonstrated facile control over porosity but formed microbeads are 
large and present a barrier for rapid molecular transport (Weber et al., 2007). The capsules 
with larger diameters than an islet itself are also expected to plug blood vessels. This can 
exert harmful effects on the patient’s liver. The diameter of encapsulated islets must be 
much smaller than that currently attained to allow transplantation of the islets into portal 
veins. Thus, new methods for the microencapsulation of islets without increasing the 
diameter of the implant are required. In this respect, modification of islet surfaces would be 
a powerful tool that can provide an artificial nurturing environment and preserve islet 
viability and function (Raymond et al., 2004; Wilson & Chaikof, 2008; Ricordi & Strom, 2004; 
Lim et al., 2011).  
In contrast to macroencapsulation, ‘microencapsulation’ can be defined as encapsulation of 
single islets or a small group of islets inside the polymer gel coating. Microencapsulation 
can be achieved via the formation of a gel shell around the islets by polymerization of a 
precursor solution around islet surfaces. Emulsification is one of the microbead formation 
methods (Iwata et al., 1992; Yang et al., 1994). PEG/Alginate was used for islets 
microencapsulation through their mixing with two-phase aqueous emulsion. The islets 
contained in emulsion microdroplets underwent cross-linking with calcium ions (Calafiore 
et al., 2006). 
During the microencapsulation process, a bio-inert coating with minimal host response and 
cell toxicity should be created. Individual islet coating offers a number of advantages over 
the macroencapsulation. An individual coating provides a better surface:volume ratio that 
allows faster diffusion of oxygen and nutrients which supports the viability of encapsulated 
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islets. Another advantage is the possibility to employ different coating techniques. The 
major requirement for the materials used for islets encapsulation is biocompatibility which 
can be evaluated by a degree of fibrotic overgrowth (Liu et al., 2010). Overgrowth of fibrous 
tissue upon microcapsule surface would affect the oxygen and nutrition diffusion by 
clogging microcapsule pores (Nafea et al., 2011). Indeed, insufficient supply of oxygen is the 
major reason for necrosis of microencapsulated islets. The biocompatibility of the materials 
used for microcapsules formation strongly depends on chemical composition of materials 
and applied purification techniques.  
Also, biocompatible materials must have selective permeability to promote the survival of 
encapsulated islets. Selective permeability should allow fluxes of oxygen, nutrients and 
metabolism products freely in and out of the protective membrane. At the same time the 
microcoating should prevent the immune system compounds such as antibodies and 
cytokines to reach the encapsulated cells. The viability and functioning of encapsulated 
islets is in majority determined by the molecular weight cutoff of the microcapsules. The 
cutoff determines the upper size limit of molecular weight that is allowed to go through 
coating. However, diffusion of the molecules very often depends on size, shape and charge 
of the molecules. Diffusion coefficient and permeability can be considered the more useful 
and informative characteristics of the cutoff. Control over the permeability can be achieved 
by varying polymer molecular weight, increasing or decreasing functional group and cross-
linking densities and polymerization conditions (Dembczynski & Jankowski, 2001). 
Molecular weight and concentration of polymer can drastically change the permeability of 
the hydrogel. It has been shown that poly(vinyl alcohol) (PVA) hydrogel with a high 
molecular weight of PVA backbone had a higher swelling ratio due to the decrease in cross-
link density (Martens et al., 2007). In radical polymerization, an increase in polymer 
concentration leads to the increase in cross-link density and decrease in the swelling ability. 
The chemical structure of hydrogel has a significant effect on hydrogel permeability. 
Presence of electrostatic interactions between charged hydrogel groups and small molecules 
will slow down the diffusion rates over time. Moreover, during time, changes in the 
diffusion coefficient occur because of changes in the hydrogel network due to physical or 
chemical absorption of proteins.  
The microcapsule shape (Sakai et al., 2006) morphology such as roughness (Bunger et al., 
2003), mechanical properties and especially stiffness of the hydrogel (Berg et al., 2004), play 
an important role in provoking immune response or fibrotic overgrowths. The importance 
of hydrogel roughness was demonstrated for implanted rough poly(L-lysine) 
(PLL)/Alginate microcapsules and only smoothing the surface by adding poly(acrylic acid) 
completely abolished the tissue response (Bünger et al., 2003). In most cases, smooth round 
surfaces had the lowest fibrosis promoting effect (Zhang et al., 2008). The most commonly 
applied materials for microencapsulation are alginate (Lim et al., 1980), agarose (Iwata et al., 
1992), PEG (Weber & Anseth, 2008) and poly(hydroxyethylmetacrylate-methyl 
methacrylate) (Dawson et al., 1987). 
3.1.1 Alginate microgels 
Alginate microcapsule production can be made under physiological conditions and provide 
an environment that allows maintaining the islets functionality and viability. 
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The microcapsule fabrication technique is based on the entrapment of islets within the 
spherical droplets that are produced by extrusion of solution containing polymer and islets 
through a needle. Two forces are usually used to control the size of droplets: an air flow that 
builds around the tip of the needle (Wolters et al., 1992), and a high voltage pulse around 
the needle tip (Halle et al., 1994; Hsu et al., 1994), the formed droplets very often require an 
additional stabilization via gelation and beads formation (Stabler et al., 2001). Cross-linking 
with metal ions, calcium and barium, and chemical or covalent cross-linking are the two 
methods generally used in microbead or microcapsule formation. Calcium cross-linked 
alginate microcapsules very often require an additional stabilization with PLL.  
Alginate is a linear polysaccharide extracted from algae with a chemical structure combining 
different ratios of ǂ-L-guluronic (G) and ǃ-D-mannuronic acids (M) and saccharides (Haug 
et al., 1974). Chemical composition of alginate may affect the biocompatibility (De Vos et al., 
1997) or/and function, and the activity of incorporated cells (Stabler et al., 2001). Guluronic 
acids and alternating mannuronic-guluronic acids have a high ability to cooperatively bind 
with divalent metal ions and form a cross-linked gel. Barium ion cross-linked gels have a 
higher stability compared to calcium ion cross-linked gels, though barium ions produce a 
more stable cross-linking only for alginate with a high ratio of guluronic acid (> 60%). 
However, ionically cross-linked alginate hydrogels undergo slow degradation under 
physiological conditions. During this process, alginate microcapsules with metal ion cross-
linking undergo slow exchange of divalent cations with sodium ions, which leads to the 
microgel degradation. Leakage of barium ions is not desirable due to their toxicity which is 
based on their ability to inhibit K+ channels at concentration greater than 5-10 mM 
(Zimmermann et al., 2000). Variations in alginate structures obtained from different alginate 
sources introduce an additional limitation for the use of the barium cations for alginate 
cross-linking. Permeability and swelling of alginate-based capsules also strongly depend on 
the ratio of the acids in alginate. Barium cross-linked G-rich alginate beads had lower 
permeability to IgG than Ca2+ cross-linked microgel. However, cross-linking M-rich alginate 
beads with Ba2+ ions leads to the permeability increase and an overall higher gel swelling 
(Mørch et al., 2006). Applying an outer coating of polycations such as PLL, or poly-L-
ornithine can readily stabilize the alginate capsules with low G-ratio (Thu et al., 1996). Thus, 
the alginate must be chosen according to a specific application. Moreover, polycations, such 
as PLL, are proinflammatory molecules responsible for the fibrotic overgrowth (King et al., 
2001) and the soluble PLL induces the cytokine production in monocytes and can be a 
reason for cellular necrosis (Strand et al., 2001). 
3.1.2 Poly(ethylene glycol)-based gels 
PEG is a less immunogenic material that is generally studied for use in islet encapsulation. 
PEG is a non-ionic hydrophilic polymer stable at physiological conditions with the highly 
hydrated polymer coils. The variation in its molecular weight can be used to control protein 
adsorption and the permeability of PEG gels by changing their porosity unlike alginate 
(Chen et al., 1998). However, the formed microbeads are larger and diffusion of molecules is 
slower (Weber et al., 2007a). 
Selective-withdrawal coating technique was used to encapsulate rat pancreatic islets within 
PEG thin coating (Wyman et al., 2007). Geometry of the capsules is determined by selective 
withdrawal throughout the bulk solution and allows the cross-linking throughout the 
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volume of the formed capsules. Mixture, containing PEG diacrylate, photoinitator 
accelerator and islets were mixed in a chamber. Once the islets were trapped into droplets, 
they were drawn into the spout. PEG polymerization was done by the exposure of the 
droplets to a green light. The free-radical polymerization of PEG diacrylate produce 
branched polymer chains. The encapsulated islets passed through the withdrawing tube 
with the same inner diameter that allowed for the same size capsules. Islets encapsulation 
required two encapsulation rounds. Despite this double coating produced capsules with 
mean thickness of 20.5 μm, islets were capable to respond to high glucose stimulation 
without a delay. 
Hydrogel network diffusion properties can be adjusted by altering the cross-link density or 
polymer molecular weight. The PEG microgel cross-linked by photoinitiated polymerization 
is a well studied system for islet encapsulation. An average pore size of the PEG gel formed 
by chain polymerization is dependent on the length of the polymer chains between cross-
links and can be used to predict and calculate the diffusion coefficient within the gel. Studies 
revealed that the molecular weight of PEG can not only affect the cross-link density, but also 
can change the concentration profile of radicals in time. Changes in the concentration of free 
radicals affect both a number of cross-linkable double bonds and diffusion limitation 
introduced during gel formation (Weber et al., 2008). More importantly, microcapsules 
produced from PEG with Mw 2000–10,000 g/mol via photopolymerization did not affect the 
viability of encapsulated islets or alter their insulin secretion. The level of glucose secretion 
observed during 1 hour of glucose stimulation was at the same level as for unmodified 
islets. Insulin secretion from islets encapsulated into 1 mm thick PEG gel was delayed at 
specific time point within stimulation period. The diffusion-related delay can be minimized 
through reducing the distance between encapsulated islets and surrounding environment 
by reducing the thickness of the gel (Weber et al., 2008).  
The created hydrogel environment is extremely different from the natural surroundings of 
islets. Indeed, cell viability is strongly dependent on cell-cell or cell-matrix interactions. For 
example, the viability of MIN6 pancreatic ǃ-cells encapsulated in just PEG-based matrix 
reduced to 17% within 10 days (Weber et al., 2007b). Mimicking the extracellular 
environment in an artificial matrix can provide additional enhancement of islets viability 
and functioning. For that, adhesive peptides or various biological components for 
promoting cell-matrix interactions can be co-polymerized within hydrogels. Thus, physical 
incorporation of laminin and collagen type IV, the most abundant proteins present in the 
extracellular matrix, was performed during formation of hydrogel from PEG dimethacrylate 
block co-polymers via photoinitiated polymerization (Weber and Anseth, 2008; Weber et al., 
2006). Such introduction of the proteins to the PEG matrix preserved the viability and 
functioning of the microencapsulated islets up to 28 days in culture. Interestingly, the ratio 
of the proteins had an effect on the level of insulin secretion from the encapsulated islets. 
For example, equal amounts of laminin and collagen IV in the hydrogel did not have any 
synergetic effect on the insulin production, while enhanced insulin secretion was observed 
for the increasing amount of laminin.  
Isolation and purification of matrix proteins is, however, complex and cost inefficient way to 
recreate extracellular matrix environment. The substitution of natural proteins by artificial 
sequences is a promising approach to resolve this issue. Recently, several therapeutic agents 
(Drucker, 2001; Drucker, 2002; Holz & Chepurny, 2003) have been proposed to increase 
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insulinotropic effect of pancreatic cells and protect them from apoptosis. The most 
promising agent is glucagon-like peptide 1 (GLP-1) that has an extremely short half-life time 
(less than 2 min) in vivo (Lee et al., 2005). Synthesis of artificial peptides with the same 
biological activities as a substitution for the natural peptide can be one of the solutions for 
this problem. Synthesis and evaluation of the synthetic glucagon like peptide functionality 
had been made by Lin et al (Lin & Anseth, 2009). The biological activity of the synthetic 
peptide physically entrapped in photopolymerized PEG microgel was not affected by 
photopolymerization. Presence of the synthetic substitute of GLP-1 in the hydrogel had a 
positive effect on insulin secretion and viability of rat islets encapsulated into the PEG 
hydrogel.  
Many cytotoxic molecules of a low molecular weight are able to easily diffuse inside the 
microgel capsules in vivo. Early islet graft failing and islet damaging occurs due to 
infiltration of pro-inflammatory cytokines, such as interleukin-1ǃ (IL-1ǃ), tissue necrosis 
factor-alfa (TNF-ǂ), and interferon-gamma (IFN-Ǆ). The size of these molecules allows them 
to freely diffuse within the matrixes commonly used in islets encapsulation. A reasonable 
approach to resolve this issue would be a further reduction of microcapsule permeability. 
However, the microcapsule pore size cannot be reduced much and still has to allow the 
permeability of insulin. The decrease in capsule size generally leads to a higher permeability 
towards cytotoxic molecules. For example, the islets encapsulated into 400-500 μm capsules 
had minor damages from cytokines, while the islets encapsulated into capsules with smaller 
dimensions become more susceptible to damage by cytokines (Basta et al., 2004). Moreover, 
a combination of cytokines and their concentration are also important factors (King et al., 
2000; De Vos et al., 2003a).  
Incorporation of molecules that can locally inhibit interactions between the small cytotoxic 
molecules and islets can be used to increase the life-time of encapsulated islets. Indeed, 
when anti-inflammatory peptide, the cytokine-inhibitory peptide IL-1RIP, had been 
introduced into PEG hydrogel even in low molar ratio, the survival of islets challenged with 
the combination of three pro-inflammatory cytokines (IL-1ǃ, TNF-ǂ and IFN-Ǆ) reached up 
to 21 days with 75 % of cells surviving while less than 25% cells survived by day 4 in the 
absence of the anti-inflammatory peptide (Su et al., 2010). Furthermore, a synergetic 
protective effect had been observed for the IL-1RIP within the microgel, with even slightly 
enhanced insulin secretion in the presence of IL-1RIP in the microgel. Importantly, the 
hydrogel was produced by mixing 4-arm PEG macromers modified with cysteine and 4-arm 
PEG with thiol-end groups. The formed hydrogel network possessed the thiol groups that 
exhibited mild reductive properties and could protect encapsulated cells from oxidative 
stress (Robertson & Harmon, 2007; Pi et al., 2007). 
Immobilization of cytokine antagonizing antibody within the hydrogel is complicated due 
to the large size of such a molecule (antibodies are usually of hundreds kDa), and protein 
stability and functioning can be altered during the immobilization process. Additionally, the 
presence of foreign antibodies in microgel structures can provoke host immune system 
response. Employing small molecules with the similar function can be one of the solutions 
such an issue. For example, small WP9QY peptide has been identified as a potential 
antagonist peptide that binds to human TNF-ǂ. This peptide was used to produce the TNF-
ǂ-antagonizing PEG hydrogel (Lin et al., 2009). When the PEG hydrogel was formed via 
photoinitiated polymerization in presence of acryl-WP9QY and adhesive peptides in a 
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precursor solution, encapsulated islets had higher insulin secretion even in the presence of 
TNF-ǂ.  
3.1.3 Cryopreservation of islets using microencapsulation 
One of the common applications of microgel beads is cryopreservation of islets. 
Cryopreservation can be achieved through freezing to preserve the cells within the polymer 
matrix. However, during freezing islets can still be damaged by extracellular ice formation 
and cell shrinkage due to dehydration nature of freezing. Recently proposed vitrification 
approach allowed avoiding these issues. In this process, the presence of certain compounds, 
e.g., sugars (Doxastakis et al., 2005), stabilizes cells through a direct substitution of water 
molecules in the outer hydrophilic part of the membrane which leads to the formation of a 
glass that prevents fusion and reduces dehydration-induced stresses (Koster et al., 2000). 
Cryopreservation by freezing had been shown to have a significant negative effect on the 
structure of agarose gel microcapsules (Agudelo & Iwata, 2008). Cryopreservation changed 
the molecular network structure of agarose gel. Structural changes affected the diffusion of 
molecules within the gel. The small molecules, such as glucose, were still able to freely 
diffuse through porous gel, while, molecules of a medium size, such as insulin, had much 
lower diffusion coefficient after gel freezing. In contrast, vitrification process applied to the 
same materials had not introduced any changes in scaffolds. Islets preserved by vitrification 
do not suffer from ice formation and shrinkage and islets viability is drastically increased. 
Rat pancreatic islets were successfully cryopreserved by freezing in alginate beads 
(Schneider & Klein, 2011) or in poly(vinyl alcohol) macro-scaffolds (Qi et al., 2010). In the 
former case, islets were mixed with alginate solution of ultra-high viscosity prior to freezing. 
Beads then were formed using an air jet droplet generator to create a certain flow rate and 
finally cross-linked with barium ions. After 7 days of cryopreservation islets were able to 
maintain normal function in vitro and normalized non-fasting blood glucose in diabetic mice 
in vivo. However, since vitrification procedure requires the presence of low molecular 
weight molecules, some of them, such as poly(vinyl pyrrolidone) and PEG of a low 
molecular weight, can exert some toxicity to the vitrification solution. For example, insulin 
release ability of the islets vitrified in the presence of those compounds decreased by 45% 
after a vitrification/warming cycle (Agudelo & Iwata, 2008).  
3.1.4 Encapsulation in epoxy-based microcontainers 
New approach for islets microencapsulation has been introduced by Gimi et al. (Fig. 2) 
(Gimi et al., 2009). They proposed to use microcontainers made by polymerization of epoxy-
based polymer. The microcontainer has a membrane containing nano-slots with the size of 
25 nm that permit the bidirectional transport of metabolites and nutritional ingredients. 
Highly cross-linked epoxy-based polymer SU-8 with high glass transition temperature, 
thermal stability and high Young’s modulus was used in fabrication of the microcontainer 
structure. The containers are capable of holding islets with dimensions upto 
200x200x200μm3. Overall device consists of two major components: a hollow cubical base 
and a nano-porous lid. The cubical base is intended for islets encapsulation, and the lid is 
sealed after an islet is placed inside the base. The base and the lid have a similar multilayer 
structure and a complicated forming procedure involving metal sputtering, polymer coating 
and nano-slot fabrication steps. Murine islets encapsulated into the microcontainers were 
viable after 48 hours in culture. The main advantage of this microcontainer approach is the 
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possibility to directly visualize the encapsulated islets due to optical transparency of the 
microcontainer material. However, apart from complex fabrication, this approach might 
require additional steps for biocompatibility adjustment of the material and needs 
additional studies on islet long-term survival and functioning.  
 
Fig. 2. Scanning electron microscope images of the microcontainer base (A) and lid (B) 
showing the 500-nm thin-membrane island structures. The thin membrane recessed within 
each island was milled with 25-nm slots using a focused ion beam. For encapsulated islets, 
the intracellular Ca2+ changes of an encapsulated islet in response to glucose and 
tetraethylammonium stimulations were measured using a spectral two-photon confocal 
microscope (C), and changes in the concentration of intracellular Ca2+ in response to glucose 
and tetraethylammonium were quantified as seen in this representative trace (D).  
Reprinted with permission from Gimi, et al., 2009 with permission  
from Journal of Diabetes Science and Technology. 
3.2 Surface modification 
Surface modification of living cells is a new approach in islet encapsulation. The main 
idea of surface modification is to reduce the size of implanted islets. This can be achieved 
by forming a conformal protective layer on the islet surfaces using various surface 
modification techniques. Both synthetic and natural polymers can be used to introduce 
various functional groups on the islets surfaces. Covalent binding to amino groups of cell 
membrane proteins, insertion of amphiphilic polymers into a cell membrane via 
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hydrophobic interactions between a lipid bilayer of the cell membrane are general 
approaches employed in cell surface modification (Fig. 3). The covalent binding of 
protective layer to islet cell surfaces is expected to be stable and be present at the islet 
surface for certain periods of time.  
 
Fig. 3. (A) Modification of cell surfaces by covalent conjugation to cell surfaces (1), by 
incorporation of molecules into the cell membrane via hydrophobic interactions (2, 3), via 
electrostatic interactions of polyions with the cell membrane (4). Immobilization of bioactive 
molecules to cell surfaces via interactions of the cell membrane with polymers (B). Adapted 
from Teramura & Iwata, 2010 with permission from Elsevier.  
3.2.1 Covalent conjugation of molecules to islet surfaces 
Thin conformal coatings based on PEG are highly attractive for cell surface modification due 
to its biocompatibility and protein-resistant properties based on PEG low interfacial free 
energy with water, its unique properties in aqueous solutions, its high surface mobility, and 
its substantial steric stabilization effects (Amiji & Park, 1993). PEGylation has been used for 
camouflaging islet surfaces to immunologically protect transplanted islets from the immune 
system (Panza et al., 2000; Lee et al., 2002; Lee et al., 2004). Methoxy-PEG-succinimidyl 
propionic acid molecules conjugated with amino groups of collagen matrix at the islet 
surface through a stable amide bond protected islets from immune cell attack (Fig. 3, A1). 
The conjugated PEG molecules have been shown to block immune cells from diffusing to 
the transplanted islets, which allowed islets to function in the diabetic recipients for several 
weeks (Lee et al., 2006a; Lee et al., 2006b; Lee et al., 2007). Another advantage of the nano-
thin PEG layer is the small size of the produced shell compared to the size of encapsulated 
islets. The small shell size and the demonstrated protection against the host immune system 
should allow transplantation into the portal vein by catheter injection and still prevent 
immune response of the host.  
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To achieve grafting of the end-functionalized PEG polymer onto the islet surfaces, islets are 
cultured in media in the presence of various concentrations of the polymer. To increase the 
amount of a grafted polymer on surfaces, the incubation time can be increased or the 
incubation step can be repeated. The grafting of methoxy-PEG (mPEG) onto the islets 
surface is usually carried out via the succinimidyl ester end groups introduced in mPEG. 
These groups couple to amino groups present in the collagen matrix around islets. 
Controlling the grafting time is important since longer grafting times can lead to diffusion of 
PEG inside the islets which may increase a chance of swelling and exposure of islets to 
outside environment. Furthermore, long grafting time increases the probability of islet 
damaging (Lee et al., 2002).  
The molecular weight of the grafted PEG is another important parameter for islet surface 
modification. Barani et al., showed that grafted mPEG of 5 and 10 kDa onto islets isolated 
from Wistar rats had a different effect on cell functioning and viability (Barani et al., 2010). 
Insulin secretion for the islets grafted with 5 kDa mPEG was at the same level as for 
unmodified islets, while overall insulin secretion from islets modified with 10 kDa mPEG 
decreased. However, its protective ability was higher which correlates well with the 
decrease in mesh size and thus less exposure to immune system. The effect of PEG 
molecular weight was also studied on porcine islets (Xie et al., 2005). The highest protection 
ability without affecting islets functional capability was found for 5-6 kDa PEG that allowed 
complete coverage of islets surface. 
In the case of two reactive succinimidyl ester end groups, additional functional molecules 
such as albumin can be brought to the islet surfaces (Xie et al., 2005). Introducing albumin 
and PEG on the surface can be used to suppress the immunogenic reactions (Hortin et al., 
1997). Presence of human albumin not only increased cytoprotection of islets but also 
significantly increased the insulin production which was possible due to increasing density 
of protective coverage with albumin presence. The so-modified islets maintained their 
functionality in vivo up to 15 days.  
Heparin is a highly sulfated glycosaminoglycan and is very often used as an injectable 
anticoagulant. Systemic delivery of heparin at therapeutic doses, however, substantially 
increases the risk of bleeding. Furthermore, the effect of soluble heparin is limited to 2-3 
hours in vivo and has no significant effect on long-term IBMIR reaction (Bennet et al., 1999). 
At the same time, heparin, immobilized on artificial surfaces which mimic the protective 
ability of the endothelial cells, demonstrated inhibition of coagulation and complement 
activation (Bennet et al., 1999). Immobilized heparin coating was successfully made on 
human, porcine and mouse islets by step-by-step incubation procedure (Cabric et al., 2007). 
Islet surfaces were first biotinylated through covalent attachment of succinimidyl ester-
biotin, then incubated with avidin and finally, heparin conjugate was covalently attached on 
the modified islets surface (Fig. 3, B). The heparin coating produced by this method was 
present of the islets surfaces at least 72 hours, though not detectable after 4-5 weeks of 
transplantation.  
Islets surface modification with other inhibitors of the coagulation cascade through 
bifunctional PEG linkers can provide another strategy to reduce IBMIR. Human 
recombinant thrombomodulin was conjugated to the islet surface through bifunctional PEG 
grafts (Stabler et al., 2007). Thrombomodulin is an endothelial cell transmembrane protein 
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which can deactivate procoagulant–proinflammatory properties of thrombin through its 
binding (Esmon et al., 2004). The formed thrombomodulin–thrombin complex leads to rapid 
inactivation of clotting factors Va and VIIIa and reduction of new thrombin generation 
(Esmon et al., 1982). This approach of thrombomodulin conjugation allowed for the 
substantial delay of clot formation upon incubation of islets in human plasma with 
preserved islet viability and glucose-stimulated insulin secretion capability. 
Despite the immunoprotective capabilities, the camouflaging layer of PEG cannot provide a 
long-term protection against small cytotoxic molecules produced by the immune system in 
response to metabolic activity of encapsulated islets after the transplantation. A combination 
of a protective coating and a low dose of an immunosuppressive drug can be a way to 
provide a suppression of host immune system without causing highly toxic effects. A low 
dose of Cyclosporine A has been shown to effectively prevent rejection of PEG-modified 
islets and support their functioning and survival up to 1 year (Lee at al., 2007). Similar effect 
was demonstrated by employing 6-arm-PEG-catechol that allowed for a coating with a 
higher density and a lower amount of immunosuppressive drug Tacrolimus (Jeong et al., 
2011). Catechol is a surface independent anchor molecule which ensured conjugation of 
PEG-catechol to collagen matrix around the islet. The survival time of 6-arm-PEG-catechol 
grafted islets was similar to that of unmodified islets. However, the administration of the 
drug increased the survival time of 6-arm-PEG-catechol grafted islet almost two times.  
3.2.2 Incorporation of molecules in the cell membrane 
Islets surface modification can be achieved via hydrophobic interactions of amphiphilic 
polymers, such as PEG-phospholipids and PVA with long alkyl chains, with lipids in cell 
membranes (Takemoto et al., 2011; Chen et al., 2011). Presence of hydrophobic parts, 
phospholipids and alkyl chains, in polymer and cell membranes are responsible for 
spontaneous incorporation of co-polymers into the lipid layers of cell membrane. The 
spontaneous incorporation is greatly affected by the length and hydrophobicity of alkyl 
chains (Rabuka et al., 2008; Teramura et al., 2007). Using this approach, the PEG-
phospholipid-based coating was modified with fibrinolytical enzyme urokinase and with a 
soluble domain of the anticoagulant, thrombomodulin (Fig. 3, B) (Chen et al., 2011). The 
immobilization of heparin, urokinase, or thrombomodulin can improve the graft survival 
after the transplantation. The maleimide-PEG-lipids were utilized to immobilize proteins on 
the islets surface through reaction of maleimide and thiol-modified proteins. However, thiol 
groups can easily form disulfide bonds under physiological conditions and that decreased 
the efficiency of the conjugation.  
Urokinase is a serine protease that activates plasminogen into plasmin, which dissolves 
fibrin blood clots. Urokinase can be conjugated onto the surface of islets to dissolve blood 
clots surrounding islets in the liver for inhibition of the cascade reactions (Takemoto et al., 
2011). Hybridization between urokinase and DNA-PEG-lipids was made due to 
complementary sequences on the protein and single strain DNA (Fig. 4). DNA hybridization 
method is versatile for conjugation of various bioactive molecules. Using different 
sequences, it was possible to conjugate different molecules on the cell surfaces. The cell 
morphology was not affected by such modification, although, urokinase activity 
disappeared after 4 days in culture.  
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Overall, surface modification achieved via hydrophobic interaction and insertion of 
hydrophobic chains into the cell membrane demonstrated a limited retention time. For PEG-
lipids this time depends on the alkyl chain length of lipid chains (Inui et al., 2010). The 
longer alkyl chains allowed PEG-lipid molecules to retain longer on the cell membrane. 
However, the overall retention time was no longer than 48 hours before the all molecules 
disappeared from the islets surfaces. Incorporation of hydrophobic molecules into the cell 
membrane leads to their uptake into the cell cytoplasm. Adding amphiphilic part to the 
structures prevents the uptake but molecules are released into the surrounding media.  
 
Fig. 4. Top: (a) Chemical structure of oligo(dT)20-conjugated PEG-lipid (oligo(dT)20-PEG-
lipid). (b) Urokinase is modified with Sulfo-EMCS to introduce maleimide groups, and then 
oligo(dA)20-SH is conjugated on urokinase through the thiol/maleimide reaction.  
(c) Oligo(dT)20-PEG-lipid is incorporated into the cell surface by the hydrophobic interaction 
between alkyl chains and the lipid bilayer of the cell membrane. Oligo(dA)20-urokinase is 
applied to cells carrying oligo(dT)20. Urokinase is conjugated on the cell surface through 
oligo(dT)20 -oligo(dA)20 hybridization. Bottom: Confocal laser scanning microscopic images 
of urokinase--modified-islets which were subjected to immunostaining for urokinase. Islets 
were modified with oligo(dT)20-PEG-lipids and then oligo(dA)20-urokinase. The urokinase-
modified-islets just after treatment, after 1 and 2 days of culture. Reprinted with permission 
from Takemoto et al., 2011. Copyright 2011 American Chemical Society. 
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3.2.3 Surface modification through electrostatic interactions 
Heparin has an affinity to a number of plasma proteins and growth factors including 
endothelium and vascular endothelium growth factors. Employing this property of heparin, 
the synthetic heparin-binding peptide amphiphile was used to immobilize heparin and, 
subsequently, growth factors on islet surfaces (Chow et al., 2010). Initial immobilization of 
the amphiphile on the islet surfaces can be achieved via electrostatic interactions of 
positively charged amphiphile and negatively charge cell membrane (Fig. 3, A4). Later, 
negatively charged heparin can be bound to the amphiphile. The so-formed amphiphile-
heparin complex coating on the islets surface was able to bind and retain growth factors up 
to 48 hours. The complex nanostructures provide extracellular matrix-like scaffold for the 
encapsulated islets for supporting their viability. Such immobilization of growth factors 
does not affect viability or function, yet, they are able to stimulate an angiogenic response in 
the islets.  
3.2.4 Immobilization of living cells on islet surfaces 
Endothelial cells on the islets surfaces have a good tolerance towards blood presence and 
can provide a protection against IBMIR. Introduction of such protective cells around islets 
can be used as an effective protection strategy. The human aortic endothelial cells were 
introduced onto isolated human islets of Langerhans by mixing of both cell types and 
incubation for several hours (Johansson et al., 2005). The clotting can be significantly 
reduced with the 90%-cell-coating present on islet surfaces. The consistency of the cell 
amounts in such coating can be improved using the PEG-phospholipid-based approach 
(Teramura & Iwata, 2009; Teramura & Iwata, 2008a). In that case, islets and human 
endoderm kidney cells were first separately biotinylated through biotin-PEG-lipid anchors 
to cell membranes with further streptavidin coating on the kidney cells (Fig. 5). 
Immobilization of the endothelium cells around islets was then made via streptavidin-biotin 
reaction. The cell enclosure was stable on the islet surfaces within 3-5 days in vitro. To 
overcome the streptavidin immunogenicity, the cell deposition was also made via the 
PolyDNA-PEG-lipid conjugate (Teramura & Chen, 2010; Teramura & Minch, 2010). Human 
endoderm kidney cells were able to rapidly proliferate forming a cell multilayer on the islets 
surfaces protecting the encapsulated islets from the host immune response. However, the 
cell oxygen consumption can result in lowered oxygen available for the encased islets. Thus, 
additional studies are necessary to clarify the short- and long-term effects of the cell 
presence on islets surfaces.  
3.3 Conformal coating of islets 
3.3.1 Layer-by-layer (LbL) approach 
The layer-by-layer (LBL) assembly of polymers based on sequential adsorption of oppositely 
charged components is one of the established methods for the preparation of thin 
polyelectrolyte multilayer films with controlled properties. The LBL represents a universal 
surface modification approach that allows for producing surface-attached films with 
controlled thickness, permeability, mechanical properties and surface chemistry. The 
technique has been recently applied to modify islet surfaces (Krol et al., 2006; Wilson et al., 
2008). The LbL modification of islet surfaces is based on alternating deposition of water  
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Fig. 5. (a) Chemical structure of biotin–PEG-conjugate (biotin–PEG–lipid). (b) Schematic 
illustration of the interaction between streptavidin and biotin–PEG–lipid at the lipid bilayer 
cell membrane. Biotin–PEG–lipid has hydrophobic acyl chains and is incorporated into the cell 
surface by anchoring into the lipid bilayer. Streptavidin is immobilized on the cell surface by 
anchoring to biotin–PEG–lipid. (c) Scheme for the immobilization of streptavidin-immobilized 
HEK293 cells on the surface of biotin–PEG–lipid-modified islets. After mixing streptavidin-
immobilized HEK293 cells and biotin–PEG–lipid-modified islets, they were cultured in 
medium at 37°C on a culture dish. During culture, HEK293 cells were spread and grown on 
the cell surface to cover the whole surface. (d) Hamster islets modified with biotin–PEG–lipid 
and immobilized with streptavidin-immobilized HEK293 cells. The HEK293 cells were labeled 
with CellTracker. Reprinted from Teramura & Iwata, 2009 with permission from Elsevier. 
soluble polymers on surfaces from aqueous solutions which results in nano-thin coatings of 
controllable thickness and composition (Decher & Schlenoff, 2002; Kharlampieva & 
Sukhishvili, 2006; Tang et al., 2006). The ultrathin conformal coating affords a faster 
response to stimulation and the possibility to bind factors or protective molecules to the 
protective ultrathin shell with the later slow triggered release of these molecules (Chluba et 
al., 2001). By selecting specific polyelectrolytes, a defined cutoff of the coating (Kozlovskaya 
& Sukhishvili, 2006) is possible, as is inhibitor binding to prevent graft rejection, microphage 
attacks, or antibody recognition (Kim & Park, 2006). Modification of the last coating layer 
can be used to support functionality of islets and reduce the immune response from a host 
system. The cutoff of the polyelectrolyte multilayer (PEM) is defined by polyelectrolytes 
used in coating formation (Krol et al., 2006).  
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3.3.2 The ionic LbL assembly  
To promote a multilayer film formation on the cell surfaces, the negatively charged cell 
surface is treated with a cationic polymer solution and the cell surface is further exposed to 
an anionic polymer solution to form an electrostatically-paired polyelectrolyte complex film 
(Fig. 3, A4). Effect of molecular weight of polyelectrolytes and the charge of outermost layer 
was demonstrated in case of the LBL encapsulation of human islets into poly(allylamine 
hydrochloride)/poly(styrenesulfonate sodium salt) (PAH)/(PSS) and poly-
(diallyldimethylammonium chloride) (PDADMAC)/PSS layers. Islets encapsulated into 
PAH/PSS and PDADMAC/PSS multilayers using a higher polycation molecular weight 
demonstrated a limited insulin release due to a lowered permeability of insulin through the 
polyelectrolyte membrane. A decrease in a polycation molecular weight resulted in larger 
pores of the polyelectrolyte membrane and restored responsive relationship between 
glucose stimulation and insulin response of the coated islets (Krol et al., 2006).  
Most cationic polymers widely used in the LbL modification of surfaces such as poly(L-
lysine) (PLL) and poly(ethylene imine) (PEI) are extremely cytotoxic and cells treated with 
the polycations can be severely damaged. Their cytotoxic effect though has been observed to 
be dependent on polycation concentration and exposure time (De Koker et al., 2007). The 
overall cytotoxicity of the polyelectrolytes originates from positive charge of polycations 
which can induce pore formation within the cell membrane causing its damage and, 
eventually, cell death (Bieber et al., 2002; Godbey et al., 1999). The high toxicity of the 
PAH/PSS LbL film was confirmed by Wilson et al (Wilson et al., 2008). They demonstrated 
that coating the murine islets with only 3 layers of PAH/PSS/PAH led to the reduction of 
islet viability by 70%. Similar effect was found for islets coated with 3 layers of PLL/alginate 
LbL film. Even 15 minutes of islets incubation with low concentration of PLL results in ~60% 
decrease in cell viability. Menger et al showed that PLL was able to pass through the lipid 
bilayer if it was previously allowed to form complex with anionic lipids (Menger et al., 
2003). PEI was found extremely toxic to the islets. This polycation destroys the cell 
membrane immediately after its interactions with the membrane surface (Teramura et al., 
2008b). The overall charge arrangement of a polycation and its interaction with the cell 
membrane strongly depends on the three-dimensional structure and flexibility of the 
polymer chains. It has been shown that polymers with highly flexible chains and a high 
cationic density will exert tremendous cytotoxicity. Thus, the polycations with globular 
structures demonstrated good biocompatibility, whereas polymers with more linear and 
flexible structure such as PLL and PEI showed higher cytotoxicity (Teramura et al., 2008b).  
Since the polycations toxicity partially depends on the polymer charge density, it can be 
attenuated by conjugating neutral molecules, such as PEG, to the critical number of amino 
groups along the polycation backbones. PEGylation of PLL is carried out through grafting of 
N-hydroxysuccinimide-PEG (NHS-PEG) chains to amino groups on PLL backbone to 
produce PLL-g-PEG. The grafted PEGs are unbranched, hydrophilic, discrete-length 
molecules in the form of Methyl-PEGn-NHS ester, where the subscript "n" denotes a number 
of the ethylene glycol units. The NHS ester end group is spontaneously reactive with 
primary amines, providing for efficient PEGylation of amine-containing molecules or 
surfaces. The methoxy(ethylene glycol) grafts were conjugated to PLL backbone through a 
covalent attachment to lysine residues (Wilson et al., 2009). Forty percent of PEG substitutes 
on the PLL chain allowed for attenuation of the PLL positive charges without any  
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Fig. 6. Cell-surface-supported PEMs were assembled on individual pancreatic islets through 
LbL deposition of PLL-g-PEG copolymers and alginate. (a) Method to assemble PEMs on 
islets. (b) Representative confocal micrographs overlaid on bright-field images of coated 
islets coated using flourescein-labeled alginate (F-Alg) with eight bilayers (8x), a single 
bilayer (1x), or treated only with F-Alg (8x, w/o cation). (c) F-Alg is localized on the 
extracellular surface of cells, confirming the cell-surface-supported nature of films.  
(d) Deposition of a single PLL/F-Alg bilayer resulted in intracellular internalization of 
alginate by peripheral cells. (e) Chemistry and reactivity of cell-surface-supported films can 
be tailored through integration of biotin- and azide-functionalized PLL-g-PEG copolymers. 
(f) Insulin secretion by islets coated with a (PLL-g-PEG /alginate)8 film (gray) and untreated 
islets (black) in response to a step-change in glucose. (g) Confocal (left) overlaid on bright-
field micrographs (right) of frozen sections of liver (L) after intraportal transplantation of 
islets (I) engineered with PEM films labeled with streptavidinCy3. Scale bars: b,e (top), 
g=50 μm; c,d,e (bottom)=10 μm. Reprinted with permission from Wilson et al., 2011. 
Copyright 2011 American Chemical Society. 
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deleterious effect on the islet viability (Fig. 6). The modification of PEG grafts with various 
functional molecules, such as biotin, hydrazide and azide, can extend the functional 
capabilities of the PLL-g-PEG-based LbL islet coatings. For example, the deposition of the 
PLL-g-PEG-biotin outmost layer on top of the PLL-g-PEG/Alginate multilayer film can 
generate surface densities of biotin functional groups comparable with that obtained by the 
treatment of islet surfaces with only NHS-PEG-biotin molecules (PEGylation/biotinylation 
through the NHS-ester coupling). Unlike the latter, the former approach is advantageous as 
it does not alter cell surface morphology and allows for controlled densities of the biotin on 
the modified islet surfaces (Krishnamurthy et al., 2010). The first successful in vivo 
transplantation of PEM engineered islets was demonstrated for the murine islets coated 
with conformal PLL-g-PEG/Alginate LbL films (Fig. 6g) (Wilson et al., 2011).  
High toxicity of most polyelectrolyte polycations limits their use in biomedical applications. 
However, natural biopolymers chitosan and alginate have more similarities with the 
extracellular matrix, are chemically versatile and have a good biocompatibility. These linear 
polysaccharides carry opposite charge and can be electrostatically bound in a PEM. The 
(Chitosan/Alginate)3 islet coating was achieved via alternate deposition starting from 
positively charged chitosan (Zhi et al., 2010). The deposition conditions had been shown to 
greatly influence the islets viability, which well correlates with difference in charge density 
and toxicity of the polycation at high and neutral pH values. Additional protective 
outermost coating layer of phosphorylcholine (PC)-modified chondroitin-4-sulfate was 
introduced to reduce non-specific protein adsorption of the film. PC-moieties demonstrated 
remarkable repelling and hemocompatible properties. Increase in the coating thickness by 
adding additional layers of (Chitosan/Alginate) up to 5 bilayers did not adversely affect 
islets viability and insulin release, and the coated islets were viable up to 5 weeks of post-
encapsulation.  
3.3.3 The LbL assembly based on covalent and/or specific interactions  
A multilayer PVA membrane formed via the layer-by-layer assembly was investigated for 
islet immunoprotective capabilities (Fig. 3, A3) (Teramura et al., 2007). In this approach 
maleimide-PEG-conjugated phospholipids were used to first modify the cell membrane 
surface to promote further interactions with PVA derivatives. It is well-known that PEG-
conjugated phospholipids can be immobilized on the cell membrane through incorporation 
of the lipid chains into the cell membrane due to their hydrophobic interactions with the 
lipid bilayers of the membrane (Iwata et al., 1992). Moreover, PEG-phospholipids are more 
compatible with cells compared to polycations used in the ionic LbL surface modification of 
islets. A layer of PVA with introduced thiol groups (PVA-SH) was covalently attached to the 
maleimide-PEG anchors via thiol-maleimide reaction. The LbL multilayer of PVA was then 
deposited by alternating immersion of the islets into PVA-SH and PVA-pyridyl disulfide 
(PVA-PD). The driving force for the multilayer formation was a thiol/disulfide exchange 
reaction between the PVA derivatives. This ultra-thin PVA membrane affected neither cell 
viability nor insulin release function. 
The LbL assembly of heparin multilayers was investigated for suppression of instant blood-
mediated inflammatory reactions for the case when islets are to be transplanted through the 
portal vein to liver (Luan et al., 2011). The heparin well-known for its anti-thrombogenic 
properties was co-assembled with human soluble form complement receptor 1 (sCR1) which 
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is a potent inhibitor of the classical and alternative complement activation pathways (Pratt 
et al., 1996). The islets surfaces were first modified with PEG-phospholipid conjugates 
bearing maleimide groups (Fig. 7). The thiol-modified sCR1 molecules were then 
covalently bound to islets through the maleimide-PEG-lipid anchors via thiol-maleimide 
reaction. Following heparin immobilization with sCR1 was possible due to its strong 
affinity to sCR1. It is known though that covalent immobilization does not allow for long-
term stability of the immobilized molecules at the cell surfaces due to fast degradation of 
the conjugation bonds. For instance, PEG-lipids gradually disappeared from the cell 
surface without uptake into the inside of cells dissociating from the cell surface into the 
medium (Teramura et al., 2008b). However, increase in the number of heparin /sCR1 
layers upto 3 bilayers allowed subsequently increase the heparin and sCR1 retention time 
on islets surfaces up to 8 days in vitro with the gradual release from the islet surfaces over 
longer time periods. As the severe IBMIR reactions, especially the activation of the 
coagulation system and the complement cascade, occur in the first 2 days after 
transplantation, the heparin/sCR1 LBL approach can be a promising method for 
protecting the transplanted islets. Nevertheless, the protective effects and anti-thrombin 
activity of the LbL coatings are to be yet evaluated in vivo.  
The LbL coating of islets based on streptavidin/biotin anchoring as a driving force for the 
LBL was also developed (Dai et al., 2007; Kizilel et al., 2010). PEGylated multilayers were 
grown using LbL assembly of biotinylated PLL and streptavidin. PEG was incorporated into 
the LbL architectures by assembly with biotin-derivatized PLL-g-PEG (Dai et al., 2007). In 
another example, the rat islet cell membranes were first biotinylated through covalent 
reaction of the membrane proteins and NHS-ester groups of NHS-PEG-biotin. The second 
layer of streptavidin was followed by a layer of a biotin-PEG conjugate with the 
insulinotropic Glucagon-like Ppetide 1 (GLP-1) (Kizilel et al., 2010). GLP-1 is a 30-amino 
acid peptide hormone produced in the intestinal epithelial endocrine L-cells. The main 
action of GLP-1 is to stimulate insulin secretion, acting as an incretin hormone, and to 
stimulate islet growth and neogenesis. Insulinotropic activity of GLP-1 is glucose-dependent 
and exerted via interaction with the GLP-1 receptor located on the cell membrane of the ǃ-
cells. Stimulation of insulin secretion due to GLP-1 immobilization at the islet surfaces can 
result in reducing the number of islets necessary for normalization of blood glucose of a 
patient. GLP1-PEG-Biotin was immobilized as an outermost layer to enhance insulin 
secretion. Islets coated with PEG-GLP-1 demonstrated enhanced insulin secretion and no 
time-delay in response to high glucose level. Streptavidin, however, is an immunogenic 
protein derived from bacteria Streptomyces avidinii and in most cases is not suitable for use in 
clinical studies. 
Obviously, multilayer PEGylation technique provides an advantage over the single layer via 
enhancing immune-protective barrier but, on the other hand, the LbL method based on 
subsequent immersion of islets in alternating polymer solutions can be time-consuming and 
thus inappropriate for clinical use. The ultra-thin multilayer build-up process was further 
modified by Hume et al to overcome this issue (Hume et al., 2011). In their approach, the 
hydrogel was formed via photoinitiated polymerization of PEG diacrylate (PEGDA) or 
methacrylate pre-cursor solutions. Proteins such as immunoglobulins, and intercellular 
adhesion molecule-2 (ICAM-2) were immobilized on the coating surface via thiol-
(meth)acrylate co-polymerization. The methacrylate-PEG was found to be more 
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cytocompatible compared to acrylate-PEG and demonstrated protective effects against T 
cells.  
 
Fig. 7. Immobilization of sCR1and heparin on the islet cell surface (top). Relative thrombin 
inactivation activities of multiple sCR1-heparin layers (1 double-layer (1DL), three-double 
layer (3 DL) on glass plates. The activities were determined after the glass plates were 
maintained in culture medium (medium RPMI-1640 containing 10% FBS) for the indicated 
periods (bottom). Reprinted from Luan et al., 2011 with permission from Elsevier. 
Thus, despite the advantages the ultrathin coating can present, chemical modification of the 
cell membrane using covalent conjugation of molecules, for example, covalent PEG binding 
via NHS-ester conjugation to the cell membrane proteins, can result in damaging of the 
membrane proteins and, consequently, in cell physiology disturbance. Moreover, the 
immunoisolation capabilities of ultra-thin hydrogel-based multilayers are still limited 
because of poor control over selective permeability towards small cytotoxic cytokines, and 
hypoxia within the gel environments. Current investigations are therefore focused on 
synthesis of hydrogels containing bioactive moieties, rather than unmodified coatings, 
aiming at “smart” protection of encapsulated islets from the damage originating from T-
cells and small free radical species.  
4. Outlook and perspective 
Though pancreatic islet transplantation has emerged as a promising treatment for diabetes, 
its clinical application, however, remains limited due to serious side effects of 
immunosuppressive therapy necessary to prevent host rejection of transplanted islets. 
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Lifelong requirement of immunosuppressive drugs has deleterious effects on ǃ-cell function 
and on host’s ability to fight disease. To protect islets from immune-mediated destruction, 
camouflaging the islet surfaces is necessary for immunoisolation and immunoprotection. 
Current islet modification strategies are challenging for transplantation due to interference 
with islet functioning, limited nutrient transport, and/or cytotoxicity. Thus, current 
strategies mostly involve either imbedding islets within thick hydrogels that have limited 
nutrient transport and require large injection volumes or covalent conjugation to islet 
surfaces, which can interfere with cell function.  
The ultra-thin coating approach possesses several advantages. Islets modified with such 
coatings can be easily implanted into liver through the portal vein, the preferable site for 
islet implantation. Islet necrosis can be avoided because of the rapid diffusion of nutrients 
and oxygen through the coating. Moreover, due to a minimal volume of the enclosed islets, 
an adequate release of insulin can be achieved in response to blood glucose changes. 
Though, despite the advantages, chemical modification of the cell membrane using covalent 
conjugation of molecules to the cell membrane proteins can result in cell physiology 
disturbance. In this respect, non-covalent modification method based on LbL can afford for 
cytocompatible coatings if non-toxic components are used. The ultrathin LbL coating allows 
for faster response to stimulation and the possibility to bind factors or protective molecules 
to the protective ultrathin shell with the later slow triggered release of these molecules. By 
selecting specific polyelectrolytes, a defined cutoff of the coating is possible, as is inhibitor 
binding to prevent graft rejection, microphage attacks, or antibody recognition. Another 
important point is that the mechanical properties of the LbL-based films can be adjusted 
through an introduction of appropriate components or the chemical modification of the 
constituents. This issue is particularly important as ǃ-cell in mature islets can still grow (Dor 
et al., 2004) causing the islet size increase. Unlike hydrogel-based ultrathin coatings, LbL 
coatings have the ability to withstand islet size increase and effectively enclose the islets for 
long periods of time. Another crucial issue is the preservation of the islet integrity because 
functionality losses were observed when islets disintegrated or fused in suspension culture. 
In this respect, the LbL technique provides a conformal and stable coating of individual 
islets.  
However, despite the significant promise of the LbL strategy for islet modification, the main 
drawback of the approach is cytotoxicity of the used compounds. Moreover, ultra-thin 
encapsulating films may not work as reliable barriers against free-radicals. Indeed, thick 
agarose microbeads or alginate microcapsules can provide a more effective shield capable of 
inactivating free radicals. This issue is particularly crucial since most inflammatory 
processes are associated with oxidative stress initiated by production of reactive oxygen 
species which can function as signaling molecules in many cell types.  
Considering the previous studies, it is important to develop new strategies for design of 
new multifunctional coatings with immunomodulatory capabilities which can permit the 
reestablishment of ECM support and maintain the physiological needs of the islets. In this 
respect, the LbL approach offers opportunities for integration of the inherent advantages of 
both islet microencapsulation and surface modification approaches. For example, 
multifunctional LbL materials designed from non-toxic biologically-active polymers can 
provide novel immunoprotective and anti-inflammatory coatings crucial for prolonged islet 
viability and functions.  
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